A 10-week inpatient study was performed to evaluate cocaine, codeine, and metabolite disposition in biological matrices collected from volunteers. An initial report described drug disposition in plasma, sebum, and stratum corneum collected from five Afrlcan-American males. This report focuses on drug disposition in hair and sweat collected from the same five subjects. Following a three-week washout period, three doses of cocaine HCI (75 mg/70 kg, subcutaneous) and three doses of codeine SO4 (60 mg/70 kg, oral) were administered on alternating days in week 4 (low-dose week). The same dosing sequence was repeated in week 8 with doubled doses (high-dose week). Hair was collected by shaving the entire scalp once each week. Hair from the anterior vertex was divided into two portions. One portion was washed with isopropanol and phosphate buffer; the other portion was not washed. Hair was enzymatically digested, samples were centrifuged, and the supernatant was collected. Sweat was collected periodically by placing PharmChek TM sweat patches on the torso. Drugs were extracted from sweat patches with methanol/0.2M sodium acetate buffer (75:25, v/v). Supernatants from hair digests, hair washes, and sweat patch extracts were processed by solid-phase extraction followed by gas chromatography-mass spectrometry analysis for cocaine, codeine, 6-acetylmorphine, and metabolites. Cocaine and codeine were the primary anal~es identified in sweat patches and hair. Drugs were detected in sweat within 8 h after dosing, and drug secretion primarily occurred within 24 h after dosing. No clear relationship was observed between dose and drug concentrations in sweat. Drug incorporation into hair appeared to be dose-dependent. Drugs were detected in hair within 1-3 days after the last drug administration; peak drug concentrations generally occurred in the following 1-2 weeks; thereafter, drug concentrations decreased. Solvent washes removed 50-55% of cocaine and codeine from hair collected 1-3 days after the last drug dose. These data may reflect removal of drug that was deposited by sweat shortly after dosing. Drug removed by washing hair collected 1-3 weeks after the last dose was minimal for cocaine but variable for codeine.
Introduction
A 10-week inpatient study was performed to evaluate cocaine, codeine, and metabolite disposition in biological matrices collected from volunteers. An initial report described drug disposition in plasma, sebum, and stratum corneum collected from five Afrlcan-American males. This report focuses on drug disposition in hair and sweat collected from the same five subjects. Following a three-week washout period, three doses of cocaine HCI (75 mg/70 kg, subcutaneous) and three doses of codeine SO4 (60 mg/70 kg, oral) were administered on alternating days in week 4 (low-dose week). The same dosing sequence was repeated in week 8 with doubled doses (high-dose week). Hair was collected by shaving the entire scalp once each week. Hair from the anterior vertex was divided into two portions. One portion was washed with isopropanol and phosphate buffer; the other portion was not washed. Hair was enzymatically digested, samples were centrifuged, and the supernatant was collected. Sweat was collected periodically by placing PharmChek TM sweat patches on the torso. Drugs were extracted from sweat patches with methanol/0.2M sodium acetate buffer (75:25, v/v). Supernatants from hair digests, hair washes, and sweat patch extracts were processed by solid-phase extraction followed by gas chromatography-mass spectrometry analysis for cocaine, codeine, 6-acetylmorphine, and metabolites. Cocaine and codeine were the primary anal~es identified in sweat patches and hair. Drugs were detected in sweat within 8 h after dosing, and drug secretion primarily occurred within 24 h after dosing. No clear relationship was observed between dose and drug concentrations in sweat. Drug incorporation into hair appeared to be dose-dependent. Drugs were detected in hair within 1-3 days after the last drug administration; peak drug concentrations generally occurred in the following 1-2 weeks; thereafter, drug concentrations decreased. Solvent washes removed 50-55% of cocaine and codeine from hair collected 1-3 days after the last drug dose. These data may reflect removal of drug that was deposited by sweat shortly after dosing. Drug removed by washing hair collected 1-3 weeks after the last dose was minimal for cocaine but variable for codeine.
Drug in these specimens was likely transferred from blood to germinative hair cells followed by emergence of drug in growing hair. These findings suggest that drug deposition in hair occurs by multiple mechanisms. " Author to whom reprint requests should be sent.
In recent years, there has been an increase in the application of hair testing for identification of drug users. The primary benefit of hair testing is that many drugs can be detected in hair for months following drug administration. Therefore, hair testing may be practical in long-term monitoring of drug use by individuals. Hair testing may also be beneficial in epidemiological studies to corroborate self-reported histories of drug use by individuals. However, there are concerns about the application of hair testing and correct interpretation of hair test results. There is not a clear understanding of the time required to obtain a positive hair test following drug use. Additionally, the relationship between dose and the amount of drug incorporated into hair has not been clearly established in controlled-dosing clinical studies. There are also concerns about the potential for interindividual differences in drug incorporation into hair due to hair type (i.e., hair color) and the potential for environmental contamination of hair of a nondrug user. Currently, an understanding of the mechanisms of drug deposition in hair is needed to address many of these issues.
Previous research suggests that drugs in blood, sweat, sebum, and skin may be transferred to hair (1) (2) (3) . The mechanisms for drug deposition in hair may be complex and involve drug transfers between many matrices ( Figure 1 ). Hair follicles are nourished with blood by capillary networks in the dermis of skin. Hair in the follicle is formed by matrix cells. These cells are located approximately 3-5 mm or deeper in the dermis and hypodermis beneath the surface of the scalp. Matrix cells undergo mitosis to produce approximately 0.3-0.5 mm of new growth each day in scalp hair (4, 5) . A potential mechanism for drug deposition in hair is diffusion of drug from blood into developing hair cells followed by the emergence of drugs in growing hair.
The epidermis is located above the dermis and is only approximately 0.07-0.15-mm thick in most body regions (6) . A metabolically active basement layer in the epidermis undergoes mitosis and produces new cells to replenish the stratum corneum (outermost layer of skin), which undergoes continual desquamation (7) . Numerous antifungal drugs have been measured in stratum corneum (8, 9) , and benzoylecgonine, a cocaine metabolite, was identified in a postmortem skin specimen (10) . Stratum corneum is constantly exposed to sweat and sebum secretions, and a possible mechanism for drug deposition in hair is that drugs in skin may be leached by sweat and/or sebum and deposited in hair.
Eccrine sweat glands in the dermis secrete sweat through coiled, tubular structures with ducts opening directly onto the skin surface (11) . The glomerulus is a plexus of blood vessels that encompasses sweat glands and supplies nutrients to metabolically active cells in these glands (12) . The main artery of a sweat gland branches into capillaries that perfuse the secretory tubule that channels sweat to the skin surface. Drugs of abuse, including cocaine (13), heroin (13) , alcohol (14) , and amphetamine (15, 16) , have been detected in sweat. A potential mechanism for drug deposition in hair is drug adsorption onto the surface of hair exposed to drug-laden sweat or drugs in sweat may penetrate the hair shaft and become bound in the interior region.
Sebaceous glands are surrounded by a complex of blood vessels similar to sweat glands. Sebum is secreted by sebaceous glands into the follicular canal in the upper region of the hair follicle approximately 0.2-0.5 mm beneath the skin surface (6) . Sebum bathes the hair shaft and disperses onto the skin surface. Antifungal drugs have been measured in sebum including itraconazole (8) and terbinafine (9, 17) . Also, Joseph et al. (2) described the secretion of cocaine, codeine, and metabolites in sebum. Drugs in sebum may be transferred to hair by mechanisms similar to those described for sweat.
An investigation of the disposition of cocaine and codeine in human subjects was performed to evaluate potential mecha- nisms for drug deposition in hair. The study timeline is illustrated in Figure 2 . Specimens of hair, sweat, stratum corneum, sebum, and plasma were collected from subjects during a 10-week inpatient study. Our first report (2) described the disposition of cocaine, codeine, and metabolites in sebum, stratum corneum, and plasma collected from five African-American male subjects. The present report describes the disposition of these drugs in hair and sweat collected from the same subjects. Sweat was collected periodically from the torso with PharmChek sweat patches during all drug administrations and throughout each week of the study. Hair was collected by completely shaving the entire scalp once each week. Sweat patches and hair specimens collected from the anterior vertex region of the scalp were analyzed by gas chromatography-mass spectrometry (GC-MS) for cocaine, codeine, 6-acetylmorphine, and metabolites.
Materials and Methods

Chemicals and reagents
Cocaine, ecgonine methyl ester, benzoylecgonine, 6-acetylmorphine, morphine, normorphine, codeine, norcodeine, co- Specimen collection days designated with an X indicate a single collection was performed. Specimen collection days marked with an R indicate that multiple collections of the specimen were made during the study day.
pated in a 10-week inpatient study conducted at the Division of Intramural Research, NIDA. Medical screening and psychological testing were performed to ensure subjects were healthy prior to study participation. All subjects provided written informed consent and were paid for their participation. The schedule for drug administrations and specimen collections is illustrated in Figure 2 . The collection of specimens began on the first study day (day 0) and continued for approximately 10 weeks. Hair was collected from the scalp, and sweat was collected periodically from the torso during the first three weeks. Beginning in week 4 (low-dose week), subjects received subcutaneous injections of cocaine HCI (75 rag/70 kg) on Monday, Wednesday, and Friday. Codeine sulfate (60 rag/70 kg) was administered orally on Tuesday, Thursday, and the following Monday. Sweat patches were worn prior to each drug administration, periodically after each drug administration at intervals up to 24 h, and during consecutive one-week intervals throughout the study. Placebo doses were administered by the subcutaneous and oral routes beginning in week 6, and specimen collections continued as described for the low-dose week.
In week 8 (high-dose week), cocaine HCI (150 rag/70 kg) and codeine sulfate (120 rag/70 kg) were administered in a manner similar to the low-dose week. Specimen collections in the high-dose week continued as described for the low-dose week.
Collection and analysis of hair
The first collection of scalp hair was performed by shaving the scalp with clippers and collecting hair separately from the frontal, temporal, nape, posterior vertex and anterior vertex regions. Hair from each region was placed in Ziplock TM bags and stored at-30~ Colgate ~ or Gillette | foam shaving cream was applied generously to the scalp, and the remaining hair stubble was removed with a disposable straight-edge razor. The straight edge razor and shavings were discarded. After the first head shaving, scalp hair (approximately 2 mm in length) was collected once each week by shaving separate regions of the scalp with Norelco | electric rotary razors. Hair collected from each region was removed from the razors and stored in labeled glass vessels at -30~ Remaining hair stubble was removed by applying shaving cream to the head and shaving with a straightedge razor. The razor and hair stubble were discarded. Throughout the entire study, subjects were permitted to rinse their hair with water; shampoo and other hair-treatment products were not allowed. Hair growth rates in each region of the scalp were determined once each week prior to hair collection by marking the length of individual hairs (approximately 10-15 hairs per region/week) on an index card. An ocular with a metric scale in 0.1-mm graduations was used to measure hair length.
Hair specimens were analyzed at the Center for Human Toxicology (University of Utah) according to a previously published method (18) . Each hair specimen was divided into two portions. One portion (approximately 20 rag) was not washed prior to enzymatic digestion. The second portion (approximately 20 rag) of hair was washed with 2 mL of 2-propanol at room temperature and vortex mixed at 400 rpm for 15 rain; the wash was decanted and discarded. These specimens were washed again with 2 mL of 0.01M phosphate buffer (pH 5.6) at room temperature for 30 min with vortex mixing at 400 rpm, and the wash was decanted and discarded. The phosphate buffer washing procedure was repeated three times. The last phosphate buffer wash and washed hair specimens were saved for analysis.
Calibration standards with unwashed hair were prepared by adding 2-2000 ng of cocaine, benzoylecgonine, ecgonine methyl ester, cocaethylene, norcocaine, codeine, morphine, 6-acetylmorphine, norcodeine, and normorphine to 20 mg of drug-free, pulverized brown hair. Calibration standards with washed hair were prepared at identical concentrations; calibration standards (2-2000 ng of drugs) were also prepared in 2 mL of phosphate buffer. Control samples were prepared with drugs in a similar manner, but with independently prepared drug standards. All samples were treated with internal standards (100 ng Tris-HC1 buffer (pH 7.4). Hair digests were centrifuged, and supernatants were collected. Hair supernatants and the last phosphate buffer wash fractions were processed by solid-phase extraction (SPE) and analyzed by positive-chemical-ionization gas chromatography-mass spectrometry (GC-MS). The method for quantitative analyses was described by Hold et a1. (18) . The limit of detection (LOD) for all analytes was approximately 0.1 ng/mg of hair and 0.1 ng/mL of phosphate buffer wash. Interassay (N = 4 runs x 3-5 replicates) coefficients of variation (CV) for controls prepared with 0.5 ng analytes/mg hair were as follows: cocaine (8.8%); ecgonine methyl ester (7.4%); benzoylecgonine (25%); cocaethylene (6.7%); norcocaine (5.6%); codeine (15.9%); morphine (20.3%); 6-acetylmorphine (8.7%); norcodeine (17.3%); and normorphine (20.6%).
Collection and analysis of sweat
Sweat was collected from the abdomen and sides of the torso of subjects with PharmChek TM sweat patches for intervals ranging from 1 h to 7 days according to previously described methods (13) . After collection, sweat patches were affixed to labeled index cards, placed in Ziplock | bags, and stored at -30~ Sweat patches were analyzed for cocaine, benzoylecgonine, ecgonine methyl ester, 6-acetylmorphine, morphine, and codeine. These analyses were performed by PharmChem Laboratories (Menlo Park, CA). Sweat patches collected in the clinical study were placed in 17 • 57-ram screw-top polypropylene tubes, and 2.5 mL of extraction buffer (methanol/0.2M sodium acetate buffer, 75:25, v/v, pH 5.0) was added. Tubes were placed in an orbital shaker operated at 200 rpm for 30 min. In opioid assays, calibration samples were prepared by adding 0-500 ng of codeine, morphine, and 6-acetylmorphine to polypropylene tubes containing drug-free PharmChek sweat patches and 2.5 mL of extraction buffer. Control samples were prepared by adding codeine, morphine, and 6-acetylmorphine to polypropylene tubes containing drug-free PharmChek sweat patches and 2.5 mL of extraction buffer. Tubes were placed in an orbital shaker operated at 200 rpm for 30 min. An aliquot (1 mL) of each calibrator, control, and clinical sample was transferred to a 16 x 125-mm glass tube, and internal standards were added (150 ng [2H3]-codeine, [2H3]-morphine, and [2H3]-6-acetylmorphine). Samples were vortex mixed for 3-5 s. The methanol fraction was evaporated under nitrogen at 50~ followed by addition of I mL deionized water and I mL of2M Tris-HCl buffer (pH 7.4). Samples were vortex mixed, 5 mL ethyl acetate was added, and samples were vortex mixed again for 20 s. Samples were centrifuged for 5 min at 2800 rpm, and the ethyl acetate fraction was collected. A 2-mL aliquot of 0.5M HCI was added to the ethyl acetate fraction, and samples were vortex mixed for 20 s. The organic layer was decanted, and the aqueous fraction was saturated with ammonium carbonate. A 5-mL aliquot of ethyl acetate was added, and samples were vortex mixed for 20 s, then centrifuged at 2800 rpm for 5 rain. The organic layer was transferred to a 10-mL conical tube and evaporated under nitrogen at 50~ Samples were prepared with 30 I~L BSTFA with 1% TMCS and heated at 70~ for 20 min. A 30-1~L aliquot of acetonitrile was added, and samples were vortex mixed and transferred to au For quantitative analyses, the peak area of the quantitative ion of each analyte in samples was divided by the peak area of the quantitative ion of the internal standard, which yielded a response ratio. The concentration of each analyte in samples was extrapolated from a curve generated from regression analysis of response ratios for calibrators. Correlation coefficients were typically greater than 0.99. The LOD was defined as the lowest concentration at which the analyte quantitative and qualitative ion ratios were within + 20% of those observed for calibration standards. The LOD was approximately 3-4 ng/mL for opioids. The interassay CV measures for patch extract buffers prepared with 12 ng of analytes per milliliter were as follows: codeine, 1.4%; morphine, 3.4%; and 6-acetylmorphine, 1.1%.
In separate assays for cocaine and metabolites, calibration samples were prepared by adding 0-750 ng cocaine, benzoylecgonine, and ecgonine methyl ester to polypropylene tubes containing drug-free sweat patches and 2.5 mL of extraction buffer. Control samples were prepared by adding cocaine, benzoylecgonine, and ecgonine methyl ester to polypropylene tubes containing drug-free sweat patches and 2.5 mL of extraction buffer. Tubes were placed in an orbital shaker operated at 200 rpm for 30 min. A 1-mL aliquot of extraction buffer from clinical samples, calibrators, and controis was transferred to separate glass tubes (16 x mg-10-mL extraction columns (United Chemical Technologies, Bristol, PA) were placed on a vacuum manifold and conditioned by adding I x I mL methylene chloride, 2-propanol (80:20, v/v) with 2% ammonia (elution solvent) followed by 2 x 2 mL methanol followed by 2 x 2 mL deionized water. After the solvents were aspirated through columns, vacuum was discontinued. Samples were added to columns and aspirated under vacuum. Columns were washed under vacuum with I x 2 mL deionized water followed by 1 x 1.5 mL 0.1M HCl. Vacuum was applied for 2 rain and discontinued. Aliquots (2 x 1 mL) of methanol were added, vacuum was applied, and columns were dried for 2 rain. Cocaine and metabolites were eluted from columns under vacuum by adding 6 • 1 mL elution solvent. Samples were dried under nitrogen at 50~ A 50-1JL aliquot of hexane was added followed by 25 Ions selected for quantitation are indicated in parentheses. Quantitative analyses were performed according to the methods described in the opioid assay of sweat patch extracts. The LOD was approximately 1-2 ng/mL for cocaine and metabolites. The interassay CV measures for patch extract buffers prepared with 12 ng of analytes per milliliter were as follows: cocaine, 4.0%; benzoylecgonine, 1.5%; and ecgonine methyl ester, 3.3%.
Instrumentation
Quantitative analysis of hair extracts was performed by positive-chemical-ionization GC-MS (Finnegan MAT 4500) with methane/ammonia as the reagent gas and helium as the carrier gas. A DB-1 column (30 m x 0.32-ram i.d., 1.0-1Jm film thickness) was installed in the GC. Chromatographic conditions were similar to those previously published for this assay (18) .
Quantitative analyses of sweat patch extracts were performed at PharmChem Laboratories by GC-MS (Hewlett-Packard 5890 GC equipped with a 5971 Hewlett-Packard mass selective detector) operated in the electron-impact mode. The chromatograph was equipped with a DB-1 column (12 m x 0.18-ram i.d., 0.4-1Jm film thickness). The column head pressure was set at 5 psi, and the GC was operated in the splitless mode using a 0.75 min purge-on time in opioid assays and 0.5 rain purge-on time in cocaine and metabolite assays. Septum purge was 2-3 mL/min and helium flow rate was 40-50 mL/min. The injection-port temperature was set at 250~ and the GC-MS interface temperature was set at 280~ For analysis of opioids, the oven temperature program was set at 170~ during sample injection followed by a 20~ increase to 290~ which was maintained for 2 min. Oven temperature was ramped at 20~ to 300~ and maintained for 3.5 rain. For analysis of cocaine and metabolites, the oven temperature program was set at 90~ during sample injection, followed by a 20~ increase to 130~ followed by a 35~ increase to 270~ which was maintained for 1.5 min. Oven temperature was ramped at 30~ to 300~ and maintained for I min.
Pharmacokinetics
Cocaine and codeine concentrations in unwashed hair were analyzed by nonlinear regression analysis with WinNonlin" (Scientific Consulting Inc., Apex, NC) software. Model-independent methods were used to obtain area-under-the-curve (AUC) measures for cocaine and codeine in hair. These measures provided an estimate of the total amount of drug incorporated into hair after dosing. AUC after the low dose was determined as follows:
Estimates of the elimination constant (~) were obtained by linear regression analysis of drug concentrations in hair collected in weeks 7-8 prior to the high-dose week. Partial AUC measures for drugs in hair were determined with specimens collected before (day 21) and after the low-dose week (day 29); partial AUC measures also were determined with specimens collected 1-3 weeks following the low-dose week. The trapezoidal method was used to calculate partial AUC measures with WinNonlin software. AUC measures following the highdose week could not be accurately determined because drug concentrations in the last hair specimens collected were near peak for most subjects. Maximum cocaine and codeine concentrations (Cm~) in hair following the low-and high-dose week were determined by visual inspection.
Statistics
The Wilcoxon signed rank test was used for statistical comparisons of Cmax measures in hair following administrations of low and high doses of cocaine and codeine. This test evaluated the null hypothesis of no significant difference between variables at an c~ level of 0.05. The Wilcoxon signed rank test was selected because of limited sample size (N = 5). Linear regression analyses of dose and plasma drug AUC versus drug concentrations in hair were not performed due to multicolinearity arising from the inclusion of multiple data points (low-and high-dose measures) from the same subject.
Results
Disposition of cocaine, codeine, and metabolites in hair
The time course for drug disposition in hair was determined by analyzing scalp hair shavings collected once each week before and after controlled drug administration. Hair from the anterior vertex region was divided into two portions. One portion of each hair specimen (unwashed hair) was not rinsed with solvents prior to enzymatic digestion and analysis. Table I lists specimen collection times, drug-administration times, and concentrations of cocaine, benzoylecgonine, ecgonine methyl ester, and codeine in unwashed hair specimens. Drug was not administered during the first three weeks of the study (washout phase). During the washout phase, cocaine and metabolite concentrations were highest in the first hair specimens collected after subjects began the study; thereafter, drug concentrations steadily decreased in hair collected over the next three weeks. Cocaine and benzoylecgonine were the primary analytes in specimens collected during the washout phase; ecgonine methyl ester concentrations in hair were typically less than 10% of cocaine concentrations. Norcocaine (0.1-0.8 ng/mg) and cocaethylene (0.1--0.6 ng/mg) were detected in the first specimens collected from subjects. Concentrations of these analytes in hair decreased steadily during the washout phase. Morphine was the only opioid in hair collected during the washout phase. Morphine (0.1-0.3 ng/mg) was present in the first hair specimens collected from four subjects. Only hair specimens collected from two subjects in weeks 2 and 3 of the washout phase contained morphine (0.1-0.2 ng/mg). Concentrations of all analytes were near the LOD (0.1 ng/mg) in hair specimens collected immediately prior to the first scheduled drug administration (day 21).
Three doses of cocaine HCI (75 rag/70 kg, subcutaneous) and three doses of codeine SO4 (60 rag/70 kg, oral) were administered on alternating days in week 4 (low-dose week); the same dosing sequence was repeated in week 8 with doubled doses (high-dose week). Cocaine and codeine were the primary analytes deposited in hair following drug administration (Table I) . Parent drugs and metabolites were detected in the first hair specimens collected within three days after completion of lowand high-dose weeks; peak drug concentrations generally occurred in hair grown during the following 8-17 days. Drug concentrations in hair declined and were near the LOD (0.1 ng/mg) at 21-23 days following the last drug administration in the low-dose week.
AUC0_~ and partial AUC measures for cocaine and codeine were determined with hair specimens collected from five subjects immediately prior to and following the low-dose week. Mean AUC0_~ measures plus or minus the standard error of the mean (SEM) for cocaine and codeine were 29.5 ng-day/mg • 4.9 and 25.1 ng-day/mg • 1.3, respectively. Mean partial AUC measures plus or minus SEM for cocaine and codeine in hair grown only during week 4 (low-dose week) were 2.2 ng-day/mg • 0.4 and 2.4 ng-day/mg • 0.5, respectively. This represents less than 10% of the total amount (AUC0_~) of drug incorporated into hair after dosing. In comparison, mean partial AUC measures for cocaine and codeine in hair grown from 1 to 3 weeks following the low-dose week were 27.3 ng-day/mg • 4.5 and 22.7 ng-day/mg • 1.1, respectively. This represents more than 90% of the total amount of drug incorporated into hair.
The primary metabolites incorporated into hair following cocaine administration were ecgonine methyl ester and benzoylecgonine (Table I) . Concentrations of these metabolites ranged from 0 to 22% of the cocaine concentrations. Norcocaine was not detected in specimens collected after the lowdose week, and norcocaine (0.1-0.2 ng/mg) was only present in 33% of specimens collected 1-3 weeks after the high-dose week.
Morphine (0.4 ng/mg) was detected in one hair specimen collected one week after administration of low doses of codeine. Normorphine (0.2 ng/mg) was present in one specimen col-lected one week after administration of high doses of codeine. Norcodeine (0.1-0.2 ng/mg) also was present in 25% of hair specimens collected 1-3 weeks after administration of low and high codeine doses.
Dose-drug concentration relationships in unwashed hair
Drug concentrations in unwashed hair specimens were evaluated to determine if there was a relationship between dose and drug incorporation into hair. Table I lists mean cocaine and codeine concentrations following low-and highdose weeks. Cocaine and codeine Cmax measures were significantly greater after high drug doses compared to low drug doses. The mean cocaine Cmax + $EM for five subjects after the low-dose week (1.8 ng/mg • 0.2) was significantly less (44%) compared with the mean Cm~ measure after the highdose week (3.2 ng/mg • 0.7). Peak cocaine concentrations in Table I * Abbreviations: COC = cocaine; BZE = benzoylecgonine; EME = ecgonine methyl ester; COD = codeine; Washout = collections prior to first scheduled drug administration.
subjects' hair ranged from 1.3 to 2.8 ng/mg after the low-dose week compared to a range of 2.4-5.5 ng/mg after the highdose week. The mean codeine Cmax + SEM for five subjects after the low-dose week (1.5 ng/mg + 0.2) was significantly less (32%) compared to the mean Cmax measure after the high-dose week (2.2 ng/mg + 0.3). Peak codeine concentrations in subjects' hair ranged from 1.1 to 2.1 ng/mg after the low-dose week compared to 1.8-3.1 ng/mg after the highdose week. Figure 3 illustrates peak cocaine and codeine concentrations in hair versus AUCo_~ measures for these drugs in plasma. AUC0~ measures for cocaine and codeine in plasma were described in a previous report (2) . For each subject, plasma AUC0_= measures for drugs and Cmax measures for drugs in hair were greater following administration of high drug doses compared with low drug doses (Figures 3A and 3B) . However, there was considerable intersubject variability in plasma AUC0_~ measures and peak drug concentrations in hair. Some subjects had higher plasma cocaine and codeine AUC0~ measures but lower Cm~x measures in hair compared to other subjects. There was also intersubject variability in AUC0_~ measures for drugs in hair following the low-dose week. These measures (N = 5) ranged from 23.7 to 48.8 ng-day/mg for cocaine and from 17.7 to 28.0 ng-day/mg for codeine. AUC0_~ measures in hair following the high-dose week could not be reliably determined because the two-week collection period following drug administration was not sufficient to characterize the terminal elimination phase for cocaine and codeine. Table II lists hair growth rates for subjects. Subjects A, C, F, and G had similar hair growth rates, but there was high intrasubject and intersubject variability in growth measurements for individual hairs. The hair growth rate for Subject H was low compared to other subjects, but the overall time course for drug disposition in hair appeared to be similar for all subjects.
Hair-growth rates
Removal of cocaine and codeine from hair by solvent washes
A portion of each hair specimen was washed for 15 rain with isopmpanol followed by three 30-rain phosphate buffer washes. Drug concentrations were measured in washed and unwashed hair. Figure 4 illustrates mean percent removal of cocaine and codeine that is due to washing hair with isopropanol and phosphate buffer prior to enzymatic digestion and analysis. The percentage of drug removed was calculated as follows:
(, (washedhaird ugconcentrati on n mg ))x100 Eq2 unwashed hair drug concentration (ng/mg)
Washing removed approximately 40% of cocaine from the first hair specimens collected three days following the last drug administration. Less than 20% of cocaine was removed by washing hair specimens collected 9-10 days after the last cocaine administration, and washing removed less than 5% of cocaine from hair collected in the following 1-2 weeks. In comparison, washing removed 40-55% of codeine from hair specimens collected one day after the last codeine administration in low-and high-dose weeks. Removal of codeine by washing was considerably greater than cocaine removal from hair specimens collected 1-3 weeks after completion of dosing ( Figure 4) . Drug concentrations were measured in the last phosphate buffer wash fraction collected from all washed hair specimens. Cocaine and metabolites were not present, but many of the last phosphate buffer wash fractions tested positive for codeine (0.2-0.3 ng/mL). Table III lists drug-administration days and drug concentrations in sweat patches collected within 48 h after the first cocaine and first codeine administration in low-and high-dose weeks. Cocaine was primarily detected in sweat patches worn during the first 24 h after drug administration. Peak cocaine concentrations for subjects ranged from 0 to 90 ng/patch after the low dose and from 0 to 63 ng/patch after the high dose. Ecgonine methyl ester and benzoylecgonine concentrations were generally less than 20% of cocaine concentrations. Peak codeine concentrations for subjects ranged from 0 to 24 ng/patch after the low dose and from 0 to 40 ng/patch after the A 5o. Table IV lists sweat-patch-collection days, drug-administration days, and drug concentrations in patches worn for 5--8-day intervals during the study. Cocaine was present in sweat patches from only one subject during the first two weeks of the washout phase. Sweat patches worn by subjects during the entire low-dose week contained from 0 to 268 ng cocaine and from 0 to 61 ng codeine; sweat patches worn during the entire high-dose week contained from 0 to 348 ng cocaine and from 0 to 53 ng codeine. Some sweat patches also contained benzoylecgonine and ecgonine methyl ester; concentrations of these metabolites were generally less than 20% of cocaine concentrations. Morphine was not detected in sweat patches worn during 5-8-day intervals following codeine administrations. Overall, there was considerable intersubject variability and no apparent relationship between drug dose and cocaine or codeine and metabolite concentrations in sweat patches.
Disposition of cocaine, codeine, and metabolites in PharmChek sweat patches
Discussion
An understanding of how drugs are deposited in hair would be a tremendous benefit to scientists responsible for interpreting hair-test results. In this study, we investigated how cocaine, codeine, and metabolites may enter hair by characterizing the time course for drug disposition in hair and different biological matrices and the relationship between dose and drug concentrations. Of particular interest was the potential for drug to be transferred between matrices. A previous report (2) described the time course for appearance and elimination of cocaine, codeine, and metabolites in sebum, plasma, and stratum washing. Hair specimens collected after the low-and high-dose weeks were divided into two portions. Prior to analysis, one portion (washed hair) of each hair specimen was washed for 15 min with 2-propanol followed by three 30-min washes with 0.01M phosphate buffer (pH 5.6). A second portion (unwashed hair) of each specimen was not treated. Washed and unwashed hair were digested in an enzymatic solution and analyzed to determine drug concentrations. Each bar represents mean percent removal of drug (_+ SEM) from hair of five subjects that is due to solvent washing. * Approximately 10-I 5 hairs were randomly selected and measured once each week over I0 weeks prior to each head hair shaving. Hair growth measurements for Subject A were obtained only during the last two weeks of the study because of a delay in development and implementation of hair measurement procedures.
corneum collected from research subjects in an inpatient clinical protocol. The present study describes the disposition of these drugs in hair and sweat collected from the same research subjects. Cocaine was administered by the subcutaneous route, and codeine was administered orally. These routes were selected to minimize health risks associated with drug administration and to avoid potential environmental contamination of matrices (e.g., hair, skin) that may occur when drugs are administered by the smoking and intranasal route. Cocaine and metabolites were detected in hair specimens collected during the washout phase prior to the first scheduled drug administration. Cocaine was also detected in sweat patches worn by one subject during the initial two weeks of the washout period. However, opioids 2.7 including 6-acetylmorphine, morphine, 2.9 and codeine were not present in sweat 3. 6 patches, and these analytes were not gen-4.2 erally detected in hair collected during 2.7 the washout period. Research subjects in this clinical study had an extensive history of illicit drug use (2) . All subjects reported occasional heroin use and also cocaine use at least three times in the ) Abbreviations: COC = cocaine; BZE ,, benzoylecsonine; EME = ecgonine methyl ester; COD = codeine.
month prior to study admission. The presence of cocaine and metabolites in hair and sweat patches collected during the washout phase can be attributed to subjects' illicit drug use prior to the beginning of the study. The highest drug concentrations were in the first hair specimens collected after subjects began the study; thereafter, drug concentrations steadily decreased in hair grown in each successive week of the washout period and were near the assay LOD prior to the first drug administration (Table I) . Consequently, it appears that drug is present in hair emerging from the scalp surface for approximately three weeks after cessation of drug use. Drugs may be deposited in hair by different mechanisms (Figure 1 ). Cocaine and codeine were detected in hair collected within three days after completion of low-and high-dose weeks. In our initial report (2), cocaine and codeine were present in plasma and sebum collected for 24-48 h after drug administration. Peak drug concentrations occurred in the first stratum corneum specimens collected one day after low-and high-dose weeks; elimination of drug in stratum corneum occurred rapidly and drug concentrations were near the assay LOD in specimens collected one week after dosing. In the present study, cocaine and codeine were detected primarily in sweat patches collected within 48 h of drug administration (Table III) . Cocaine was not generally present in sweat patches that were applied three days after drug administration and worn for approximately one week (Table IV) . Therefore, transfer of drugs from blood, sebum, sweat, and stratum corneurn to hair most likely would have occurred prior to the first hair collection (1-3 days) following drug administration. If all of the drug in these hair specimens was transferred from sebum, stratum corneum, and sweat, these mechanisms would account for less than 10% of the total amount of drug deposited in hair following drug administration (based on partial AUC measures for cocaine and codeine in hair following the lowdose week).
Other studies have described the potential for transfer of drugs from sweat, sebum, and skin to hair (1,2). Cone (19) detected codeine in beard collected one day following drug administration to a human volunteer. The investigator suggested that drug in sweat may have been deposited in hair. Kidwell and Blank (20) collected scalp hair from a patient following administration of dihydrocodeine for one week. They detected drug in hair that had grown from the scalp prior to the first drug administration. Henderson et al. (21, 22) detected cocaine-ds in hair specimens collected 8 h to 3 days following cocaine-ds administration to human volunteers. These findings could be explained by transfer of drug from sweat and sebum to hair. Additiona!ly, the disposition of cocaine and metabolites is typically similar in hair (21, 23) and sweat (13, 21) . Cocaine is the primary analyte in hair and sweat following drug administration, and relatively low concentrations of cocaine metabolites (benzoylecgonine and ecgonine methyl ester) are often present in these matrices. A similar dispositional profile for these analytes was observed in sebum and stratum corneum in our initial study (2) and in sweat and hair in this study.
In the present study, shaving the entire scalp once each week limited the potential transfer of drugs from sweat, sebum, and stratum corneum to hair grown only in the week during drug administration. Biological secretions could deposit drugs along the entire hair shaft in situations when a drug user's hair is several inches in length at the time of drug administration. Conversely, drugs along the hair shaft may be leached from hair by biological secretions. Drugs in hair may also undergo axial or radial diffusion in hair over several weeks after drug use (22, 24, 25) . These processes could result in a diffuse pattern of drug deposition along the hair shaft. A weekly hair shaving procedure was performed in this study to minimize the potential for spreading of drugs along the hair shaft and possible drug loss from hair that may have resulted from exposure to biological secretions and bathing during the 10-week study. These phenomena would have precluded an assessment of how drugs are initially deposited in hair. Further clinical research is needed to determine the ultimate fate of drugs deposited in hair that is collected several weeks or months after drug administration.
Interestingly, data collected in this study demonstrated that cocaine and codeine disposition in hair and plasma (2) was dose-dependent within subjects, but there was no apparent relationship between dose and drug concentrations in sebum, sweat, and stratum corneum. Peak drug concentrations in hair of each subject were 1.5-1.8-fold greater following the high-dose week compared with the low-dose week. Similarly, Cone (19) reported that codeine and morphine incorporation into the beards of two subjects appeared to be dose-dependent. Baumgartner et ai. (26) reported a positive correlation between self-reports of drug use and cocaine, heroin, and phencyclidine concentrations in hair. Ferko et al. (27) demonstrated a positive correlation between administered doses of cocaine and cocaine and benzoylecgonine concentrations in hair. In the present study, higher concentrations of ecgonine methyl ester and benzoylecgonine were generally present in hair grown after the high-dose week compared with the low-dose week (Table I) . However, cocaine metabolite concentrations in hair were relatively low compared with cocaine. Ecgonine methyl ester concentrations in plasma were considerably lower than cocaine (2); consequently, less ecgonine methyl ester may have been available for diffusion from blood and incorporation into hair. Greater incorporation of cocaine into hair compared to benzoylecgonine did not appear to be due to differences in plasma drug concentrations (2) . Differences in the physicochemical properties of cocaine and benzoylecgonine (i.e., charge state, iipophilicity, plasma protein binding) may have affected drug diffusion from blood and subsequent drug incorporation into hair (28) .
Considerable interindividual differences were observed in cocaine and codeine incorporation into hair. Drug concentrations were higher in the hair of some subjects after the low dose than drug concentrations in the hair of subjects after the high dose ( Figures 3A and 3B) . Additionally, codeine incorporation into hair of some subjects was greater than cocaine incorporation, although codeine was administered at lower doses and by a less bioavailable route than cocaine. These findings did not appear to be related to interindividual differences in drug disposition in plasma or differences in hair-growth rates (Table  III) . Henderson et al. (21, 22) observed considerable intersubject variability in drug incorporation into hair following controlled cocaine-ds administration to volunteers. They suggested that these findings may have been related to individual differences in the rate of secretion of drug-laden sweat and sebum. In the present study, there was considerable variability between subjects in drug secretion in sweat (Table II) and sebum (2) . It is possible that drug incorporation into subjects' hair may have varied in part because of differences in the amount of drug secreted in sweat and sebum. However, most of the drug incorporated into hair was present in specimens collected 1-3 weeks after drug administration, and drugs were not detected in sweat and sebum during this period. Other factors could have affected drug deposition in hair. Differences between individuals in the number, type, and affinity of drug-binding sites in hair may have affected drug incorporation. Differences in blood flow in the skin of subjects' scalps may have affected the amount of drug available for incorporation into hair. There also may have been differences between subjects in plasma protein binding of drugs that could have affected drug deposition in hair.
Peak drug concentrations in hair occurred 1-2 weeks after elimination of drugs in sebum, plasma, sweat, and stratum corneum was complete. Drug sequestered in hair matrix cells in the root would be present in hair emerging from the follicle between 1 and 3 weeks following drug administration because follicles are generally located 3-5 mm beneath the scalp, and the typical hair growth rate for subjects in this study was approximately 2 ram/week. Hair grown 1-3 weeks after drug administration contained more than 90% of the total amount of drug incorporated into hair following the low-dose week. These data suggest that a primary mechanism for cocaine and codeine incorporation into hair was diffusion of drug from blood into matrix cells in the hair root (Figure 1 ). Other investigators have suggested the same mechanism for drug incorporation into hair. Gygi et al. (29) measured codeine and metabolites in plucked hair (hair shaft and bulb) from rats following codeine administration. Drug was detected in plucked hair within 1 h after codeine administration. The investigators reasoned that the bulb of plucked hair was wet with extracellular fluid (e.g., blood) containing drugs that could have been incorporated into cells in the hair bulb. Gwent et al. (30) evaluated the time course for incorporation of cotinine into beard of male volunteers. Cotinine appeared in beard collected at three days following drug administration, and peak drug concentrations occurred at five days. These findings were attributed to the transfer of drugs from blood to developing hair cells in the follicle of beard. The investigators reasoned that transfer of drug from sebum to hair was unlikely. There is an eight-day interval between sebum synthesis in sebaceous glands and secretion into the follicular canal (31) . Therefore, secretion of drug in sebum was expected to have occurred when drug was not detected in beard (eight days after drug administration). The investigators also indicated that transfer of drugs from sweat to beard was unlikely because drug was not detected in beard collected two days following drug administration when the beard was expected to have been exposed to drug secreted in sweat. In another study, Cone (19) reported the appearance of morphine and codeine in beard at 7-8 days after drug administration to human volunteers. Peak drug concentrations occurred 1-2 days following initial appearance of drugs in beard. The delay in appearance of drugs in beard following drug administration was attributed to transfer of drugs from blood into cells in the hair bulb followed by emergence of drugs in hair grown during the following 7-8 days.
An important focus of this study was to evaluate the effect of washing hair specimens with solvents and buffers. The truncated hair wash procedure described by Baumgartner et al. (32) was employed in the present study. This procedure (26, 32) was developed to remove drugs that may be deposited on the surface of hair because of external contamination (i.e., drugs in aerosols, aqueous solutions, and biological secretions). In this study, washing removed approximately 40-50% of the drugs in hair specimens collected within three days following completion of low-and high-dose weeks (Figure 4) . The removal of substantial amounts of cocaine and codeine by washing hair specimens may reflect removal of drugs deposited near and/or on the surface of hair by sebum and sweat. In comparison, washing removed only a small amount of cocaine in hair collected approximately three weeks following completion of lowand high-dose weeks (Figure 4) . Diffusion of cocaine from blood into developing hair cells may have sequestered drug. Cocaine in these hair specimens may have been more resistant to removal by washing because of entrapment or binding within hair cells. A similar mechanism for codeine sequestration in hair may also have occurred. However, there were differences in cocaine and codeine removal that were due to washing hair specimens. Washing removed 30-40% of codeine but less than 5% of cocaine from hair that was collected three weeks after completion of drug administration (Figure 4) . Additionally, codeine was present in the last phosphate buffer wash fraction of most hair specimens, but cocaine was not detected. Greater loss of codeine by washing hair may be due to differences in drug sequestration in hair (i.e., greater affinity of cocaine for binding sites compared to codeine; different mechanisms for cocaine and codeine incorporation into hair).
In summary, the present study demonstrated that drug deposition in hair may occur by multiple mechanisms. Cocaine and codeine appeared in the first hair specimens collected within three days following drug administration in low-and high-dose weeks. Drugs in these hair specimens may have been transferred from sebum, sweat, and stratum corneum. Drugs may have been adsorbed onto the surface of hair or penetrated the hair shaft and become bound in the interior of hair. Peak drug concentrations occurred at 1-2 weeks following low-and high-dose weeks when drugs were not present in plasma, sebum, stratum corneum, and sweat. Drugs in these hair specimens likely diffused from blood into matrix cells in the follicle followed by emergence of drugs in growing hair. This appeared to be a primary mechanism for drug deposition in hair. However, interpretation of these findings was hindered in part by the study design. By shaving the entire scalp each week, the transfer of drugs from sweat, sebum, and stratum corneum to hair was limited to hair grown only in the week during drug administration. Further study is needed to determine if drugs in biological secretions are deposited only in hair near the surface of scalp, if drugs in secretions can be transferred to sections of hair distal to the scalp (i.e., 5-10 cm from scalp surface), and if secretions can leach drug from hair and/or "smear" drug along the hair shaft. Other limitations in this study were the size and homogeneity of the subject population (five African-American males). Research is needed to examine drug disposition in hair, plasma, seburn, sweat, and skin collected from different populations (i.e., African-American females and Caucasian males and females) to determine if there are differences in the mechanisms of drug incorporation into various hair types. In vitro, preclinical, and clinical studies (22, 29, 33, 34) suggest that incorporation of certain drugs differs between hair types (i.e., attributable to hair color). Therefore, inclusion of different populations of subjects in future clinical studies is warranted.
